Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593276 | 1.00 | MAPK1 (0.77) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL8744962 | 0.91 | MAPK1 (0.59) | MAPK1POLBCA2HDAC6HDAC3 | |
| SCHEMBL26417166 | 0.89 | MAPK1 (0.56) | MAPK1POLBHDAC6HDAC3HDAC4 | |
| SCHEMBL428355 | 0.87 | MAPK1 (1.00) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL16688444 | 0.85 | MAPK1 (0.76) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL9183154 | 0.83 | MAPK1 (0.90) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL5658185 | 0.81 | MAPK1 (0.87) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL10659200 | 0.81 | MAPK1 (0.86) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL10865398 | 0.81 | MAPK1 (0.86) | MAPK1CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL5655215 | 0.81 | MAPK1 (0.86) | MAPK1CYP1A2CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| WO-2011154308-A1 | NEW COMPOSITIONS AND CELL THERAPY METHODS FOR THE TREATMENT OF CIRRHOSIS | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2011-12-15 | — | — | WO | disclosed |
| US-20110250179-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2011-10-13 | — | — | US | disclosed |
| US-20110212060-A1 | USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSIDAD DEL PAIS VASCO (ES) | 2011-09-01 | — | — | US | disclosed |
| EP-2322147-A1 | USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Universidad del Pais Vasco (ES) | 2011-05-18 | — | — | EP | disclosed |
| EP-2316970-A2 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | Traslational Cancer Drugs Pharma, S.L. (ES) | 2011-05-04 | — | — | EP | disclosed |
| US-20100272812-A1 | RGD-MODIFIED ALGINATE MICROPARTICLES AS A DRUG RELEASE SYSTEM | UNIVERSIDAD DEL PAIS VASCO (ES) | 2010-10-28 | — | — | US | disclosed |
| EP-2174656-A1 | MICROPARTICLES OF ALGINATE MODIFIED WITH RGD AS A RELEASE SYSTEM FOR MEDICINES | Universidad del Pais Vasco (ES) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | MAPK1 1568/4885CYP1A2 4058/4885CYP2C9 4202/4885 |
| US-20110250179-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | MAPK1 1568/4885CYP1A2 4058/4885CYP2C9 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.